Sachin Kasera

Hi, sir. C ongrats for the progress that we achieved in the last 2-3 years. I just had one clarification. You have one of your slides number 12 in the presentation you have mentioned that the pre -registration of the Phase-III molecules, which used to earlier classify as part of development are now part of commercial. And so this is effective, which financial year you have done the reclassification?

Sure. And so when I understand that quarter -to-quarter is not fair, but if we look around 9 months-to-9 months, and if I look at your filing, the number of products in preclinical Phase-I, Phase-II, Phase-III are more or less the same.

My second question on peptide, we have a fairly large CAPEX. Over a period of time, once it is fully utilized, can you give us some sense in terms of what type of revenue we could see 2-3 years after the commercialization of the peptide block? Thank you.